Israel’s Teva reported that Phase III trial results for its asthma treatment reslizumab reduced the frequency of attacks by 50 – 60% compared to placebo.
http://www.globes.co.il/en/article-teva-reports-positive-phase-iii-asthma-drug-results-1000968700